Amicus Therapeutics (LTS:0HF9) Asset Impairment Charge : $0.7 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amicus Therapeutics Asset Impairment Charge?

Amicus Therapeutics's Asset Impairment Charge for the three months ended in Jun. 2024 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was $0.7 Mil.

Amicus Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Amicus Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Asset Impairment Charge Chart

Amicus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

0.10

18.18

2.73

Amicus Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Asset Impairment Charge	Get a 7-Day Free Trial															2.06	0.30	0.37	-	-

Amicus Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.7 Mil.

Amicus Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (LTS:0HF9) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

FOLD:USA AM6:Germany AM6:Germany

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines